Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS Proposed National Coverage Decision Topic List Exempts Biopharma

This article was originally published in RPM Report

Executive Summary

The Centers for Medicare & Medicaid Services’ new list of “potential” topics for National Coverage Decisions includes 33 separate ideas, most proposed by the public. Not one is directly related to a biopharma topic. CMS’ coverage team swears it remains interested in drug-related coverage issues—but still, this is one list it is nice not to be on.


Related Content

Drugs Not ‘On Radar’ For Medicare Coverage Review, Official Says
The Value of Knowing: CMS Rejects Coverage of Lilly’s Amyvid – Except As Tool For Further Research
The Zaltrap Price Debate: Less Than Meets The Eye
CMS Takes A Look At Alzheimer’s With Lilly's Amyvid In Mind
CED and Personalized Medicine: A Perfect Match?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts